Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer. Celator’s proprietary technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations, incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. For more information, visit the company’s website at www.celatorpharma.com.